share_log

UBS Maintains Buy on Merck & Co, Lowers Price Target to $142

Benzinga ·  Jul 31 11:46  · Ratings

UBS analyst Colin Bristow maintains Merck & Co (NYSE:MRK) with a Buy and lowers the price target from $148 to $142.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment